Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Non-Current Deffered Revenue (2020 - 2025)

Historic Non-Current Deffered Revenue for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $193.1 million.

  • Foghorn Therapeutics' Non-Current Deffered Revenue fell 2261.53% to $193.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.1 million, marking a year-over-year decrease of 2261.53%. This contributed to the annual value of $234.5 million for FY2024, which is 1255.36% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Non-Current Deffered Revenue of $193.1 million as of Q3 2025, which was down 2261.53% from $206.8 million recorded in Q2 2025.
  • Over the past 5 years, Foghorn Therapeutics' Non-Current Deffered Revenue peaked at $322.7 million during Q4 2021, and registered a low of $11.9 million during Q1 2021.
  • In the last 5 years, Foghorn Therapeutics' Non-Current Deffered Revenue had a median value of $266.1 million in 2024 and averaged $230.1 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first surged by 256937.19% in 2022, then plummeted by 2261.53% in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Non-Current Deffered Revenue stood at $322.7 million in 2021, then fell by 5.8% to $304.0 million in 2022, then dropped by 11.8% to $268.1 million in 2023, then fell by 12.55% to $234.5 million in 2024, then dropped by 17.64% to $193.1 million in 2025.
  • Its Non-Current Deffered Revenue was $193.1 million in Q3 2025, compared to $206.8 million in Q2 2025 and $222.4 million in Q1 2025.